Accelerating shifts from reactive to proactive health and a deeper understanding of the link between health and nutrition are driving sustained growth in the Asia-Pacific prebiotic food supplements market, says microbiome specialists Clasado Lifesciences
Prevention And Science Trends Driving Double-Digit Growth In APAC Prebiotics Market
“For consumers around the globe, and the APAC market is a prime example, there is an ongoing shift from reactivity to proactivity,” explains Clasado Biosciences’ David Mharakurwa. Alongside an increasing awareness of the links between gut health and wellness, such trends are driving strong growth in the region for nutraceuticals like Clasado’s Bimuno GOS.
More from Asia
• By
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.
• By
TikTok dietary supplement sales in Thailand grew by an astonishing 635% in 2024, while sales via Vietnam's and Malaysia's traditional e-commerce platforms increased by a still impressive 73% and 83% respectively.
• By
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.
• By
Organizations representing APAC health and medicines regulators and the consumer health industry respectively have agreed to “recognize the importance of self-care as a fundamental pillar of health and wellbeing” and “affirm our dedication to advancing self-care as an essential component of Universal Health Coverage.”
More from Geography
• By
“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.
• By
TikTok dietary supplement sales in Thailand grew by an astonishing 635% in 2024, while sales via Vietnam's and Malaysia's traditional e-commerce platforms increased by a still impressive 73% and 83% respectively.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.